Targeted therapies have benefited patients with EGFR and Alk mutant lung cancers, but for decades, therapeutic options for patients with Kras mutant lung cancer did not extend beyond chemo/radiotherapy or surgery, contributing to the low survival rates (Fidias and Novello, 2010; Lynch et al., 2004; Molina et al., 2008). The gene discussed is KRAS; the disease is lung cancer.